Imaging Biomarkers in Metastatic Prostate Cancer

Presenters: Matthew Silva Ph.D. | CEO, Invicro

Phillip Kuo M.D. Ph.D. | Senior Medical Director, Invicro

The second most common cause of cancer death in men is prostate cancer. The most severe form of the disease is metastatic castration-resistant prostate cancer (mCRPC), which is marked by soft tissue and bone metastasis that progress even in the presence of reduced hormone levels. Modern treatment regimens have demonstrated overall survival at 5 years at ~25%, which is great progress, however, there remains a high unmet medical need for treatment as well as improved biomarkers.

The diagnosis, staging, treatment planning and monitoring of mCRPC relies on a combination of clinical tests, including several standard and advanced imaging methods.

In this webinar, Dr. Silva and Dr. Kuo will review standard of care imaging in mCRPC and introduce nuclear medicine methods that monitor disease and drug targets, such as PSMA. They will also review multi-parametric MRI methods that aim to improve the characterization of disease and monitoring of drug treatment. Finally the webinar will demonstrate how our advanced analytical tools can assist radiologists and oncologists in the evaluation of metastatic disease status and response to therapy.

Dr. Silva is CEO of Invicro and leads the strategic vision and mission to support the the drug discovery and development community.

Dr. Silva holds a PhD in Biomedical Engineering from Worcester Polytechnic Institute and brings 17 years of diverse imaging experience from pharmaceutical and contract research organizations. Prior to Invicro, he was Senior Director of Translational Biology at Vertex Pharmaceuticals, where he ran the imaging and histopathology groups. Previously, he led imaging groups at Amgen, Millennium and Takeda Pharmaceuticals, focusing on the broad use of imaging biomarkers to support drug discovery and development.

Dr. Kuo is a tenured Professor in the Departments of Medical Imaging, Medicine, and Biomedical Engineering at the University of Arizona. Beyond his academic work, Dr. Kuo has vast experience as a consultant, reader and speaker for CROs and pharmaceutical companies. Dr. Kuo has authored over 90 publications and has received numerous grants covering a diverse range of disciplines. Dr. Kuo received his A.B. from Harvard University, M.D. and Ph.D. from the University of Virginia, completed his Internal Medicine Residency at UCLA Medical Center, Diagnostic Radiology Residency at Yale New Haven Hospital, and Nuclear Medicine Fellowship at Yale New Haven Hospital. At Invicro, he supports the design, performance, and analysis of clinical trials and also supports regulatory approval and post-approval activities such as reader training.

Imaging Biomarkers in Metastatic Prostate Cancer

MATTHEW SILVA, PH.D.

CEO, Invicro

PHILLIP KUO, M.D., PH.D.

Senior Medical Director, Invicro